Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan and represents the final sale under that plan. Following this sale, Schoenberg holds 119,763 Ordinary Shares directly.
UroGen Pharma Ltd. reported proposed sales of common stock by an affiliate via Form 144. The filing lists two dispositions of 10,000 shares each sold on 05/08/2026 and 06/22/2026 for $300,048 and $350,143, respectively, and references a stock option exercise dated 01/27/2023.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction at a weighted average price of $35.01 per share, with trades ranging from $35.00 to $35.08, under a pre-adopted Rule 10b5-1(c) trading plan. Following this sale on June 22, 2026, he directly holds 129,763 Ordinary Shares.
UroGen Pharma director Daniel George Wildman received new equity awards. He was granted 8,000 restricted stock units and stock options for 10,000 ordinary shares at an exercise price of $34.99 per share. Both the RSUs and options vest in equal quarterly installments over one year, contingent on his continuous service.
UroGen Pharma Ltd. director James A. Robinson Jr. reported equity awards that increase his potential ownership in the company. On June 22, 2026, he received 8,000 restricted stock units (RSUs), each representing one ordinary share upon vesting. He was also granted stock options on 10,000 ordinary shares with an exercise price of $34.99 per share and an expiration date of June 22, 2036. Both the RSUs and the option shares vest in equal quarterly installments over one year, contingent on his continued board service. After these grants, his reported holdings from these awards are 8,000 RSUs and 10,000 options, reflecting routine director compensation rather than open‑market trading.
UroGen Pharma Ltd. director Stuart Holden received a grant of stock options covering 20,000 ordinary shares. The options have an exercise price of $34.99 per share, expire on June 22, 2036, and vest in equal quarterly installments over one year, subject to his continuous service. Following this grant, he holds 20,000 options directly.
UroGen Pharma Ltd. director Cynthia M. Butitta received new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share. These RSUs will vest in equal quarterly installments over one year, so the award is earned gradually as service continues.
She was also granted stock options covering 10,000 ordinary shares at an exercise price of $34.99 per share, expiring on June 22, 2036. The option shares vest in equal quarterly installments over one year, aligning her incentives with long‑term shareholder value rather than reflecting any open‑market buying or selling.
UroGen Pharma Ltd. director Leana Wen reported receiving new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share, and 10,000 stock options to purchase ordinary shares at an exercise price of $34.99 per share.
The RSUs and the shares underlying the options will vest in equal quarterly installments over one year, contingent on her continued service under the company’s 2017 Equity Incentive Plan. These are grants and do not involve any open-market buying or selling of shares.
UroGen Pharma Ltd. director Arie Belldegrun received a grant of stock options covering 20,000 ordinary shares. These options were granted at an exercise price of $34.99 per share and expire on June 22, 2036. The underlying 20,000 ordinary shares will vest in equal quarterly installments over one year, subject to the director maintaining Continuous Service under the company’s 2017 Equity Incentive Plan. After this grant, the filing shows 20,000 derivative securities held directly, with no additional option positions listed.
UroGen Pharma Ltd. reported results of its 2026 Annual Meeting of Shareholders. Investors approved amended and restated Articles of Association that, among other changes, tie eligibility for shareholder proposals to requirements under Israeli Companies Law.
Shareholders also approved a Compensation Policy Amendment related to directors’ and officers’ insurance and an amendment to the 2017 Equity Incentive Plan to increase ordinary shares authorized for issuance under the plan by 1,000,000 shares. All seven director nominees were elected, executive pay received advisory approval, and PricewaterhouseCoopers LLP was ratified as independent auditor until the 2027 annual meeting.